Anagenics Limited · ASX:AN1
Anagenics — Merger or Acquisition (August 2023)
12 slides from Anagenics's merger presentation, Aug 22, 2023
Slide 1: Setting the pathway to profitable growth
ASX: AN1 Setting the pathway to profitable growth MARKET ANNOUNCEMENT
Slide 2: Disclaimer
Disclaimer Forward Looking Statement and Disclosures. hereof. Recipients should not construe the contents of this Anagenics assumes no obligation to update the information This presentation is not making any offer, inducement, presentation (or any discussions relating to it) as legal, tax, herein. N
Slide 3: Face MediGroup purchase rounds out Anagenics' professional beauty vertical strategy in Australia
THE HEADLINE STORY Face MediGroup (FMG) purchase rounds out Anagenics’ professional beauty vertical strategy in Australia Anagenics has a clear strategy for profitable growth in the beauty and wellness space through its inorganic pursuit of profitable businesses, delivery of simple customer platform
Slide 4: The Context
The Context MARKET ANNOUNCEMENT – FACE MEDIGROUP ACQUISITION 4
Slide 5: Anagenics has laid the foundations for sustainable profitability
THE CONTEXT Anagenics has laid the foundations for sustainable profitability NOVEMBER 2021 APRIL 2023 JUNE 2023 JUNE 2023 AUGUST 2023 Losses reduced by 57% FY23 INORGANIC TALENT PROACTIVELY SOUGHT SOUGHT SYNERGIES ACQUISITION TO REDUCE LOSSES AND OPERATIONAL OF FACE MEDIGROUP Successful transaction
Slide 6: Australian beauty sector remains resilient
THE CONTEXT Australian beauty sector remains resilient Research reveals the global professional beauty services market will see a 5% rise between 2023-2030 01 02 03 Australian property Australia’s headline Australian interest rates likely prices stabilised inflation outlook to have peaked whilst oth
Slide 7: The Face MediGroup Transaction
The Face MediGroup Transaction MARKET ANNOUNCEMENT – FACE MEDIGROUP ACQUISITION 7
Slide 8: Enables Anagenics to further penetrate the Australian professional beauty sector
FACE MEDIGROUP TRANSACTION FY22A FY23A Face MediGroup Anagenics Pro-Forma Face MediGroup Anagenics Pro-Forma Enables Anagenics to further Revenue Cost of sales 3,963 2,546 9,235 4,170 13,198 6,716 4,910 3,389 9,320 4,811 14,230 8,200 penetrate the Australian Gross Profit 1,417 5,065 6,482 1,521 4,50
Slide 9: Asset sale deal structure
FACE MEDIGROUP TRANSACTION Asset sale deal structure AN1 SCRIP DEFERRED CASH CONSIDERATION LOAN TERMS CONDITIONAL DEFERRED CONSIDERATION $250,000 $500,000 $350,000 $300,000 $300,000 Issued at the 30 day Payable in 3 tranches, funded by AN1 balance Adoption of long-term loans Cash payable post FY24 s
Slide 10: Australia's beauty industry will continue to evolve…
THE PATH AHEAD Australia’s beauty industry will continue to evolve… REGULATIONS MALE CUSTOMERS COMPETITOR TECHNOLOGY INNOVATION LANDSCAPE IS MOVING FAST for professional products Increasing male Product, channel, and therapists continues customer segment Streamlined structures, Online scheduling, di
Slide 11: Anagenics will look to drive the sector's innovation and change
THE PATH AHEAD BUILD ON RETAIL PROOF OF CONCEPT BRANDED RETAIL Anagenics There is an opportunity to build Review future opportunities will look to drive a professional scalable retail brand to expand into Branded physical targeting express treatments with a retail supporting product offering the sec
Slide 12: Unlock growth opportunities with Anagenics
Unlock growth opportunities with Anagenics Contact us today to find out how you can leverage the opportunity Authorised for release to the ASX by AN1 Board of Directors Anagenics Limited Suite 204, Level 2 55 Clarence Street Sydney, NSW, 2000 Sandy Beard Scott Greasley info@anagenics.com Chairman CE